|
Mutation Information
|
Mutation Site
|
R263K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Combined Mutation
|
in.E138K+in.R263K;in.H51Y+in.R263K |
|
Relevant Drug
|
dolutegravir (DTG) |
Literature Information
|
PubMed PMID
|
25394027
|
|
Published Year
|
2014 |
|
Journal
|
Journal of the International AIDS Society |
|
Title
|
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. |
|
Author
|
Wainberg M,Anstett K,Mesplede T,Quashie P,Han Y,Oliveira M |
|
Evidence
|
The R263K mutation alone conferred an approximate 3-fold level of resistance to DTG and a 40% loss in viral replicative capacity and recombinant integrase activity.
|
|
|
HIV Mutation Detail Information